Results 31 to 40 of about 681,060 (251)
Metyrapone in treatment-resistant depression [PDF]
Therapeutic Advances in Psychopharmacology, 2012 Depression affects a significant proportion of the population, with 1-year and lifetime prevalence of 3–5% and 10–30% respectively. Full remission is achieved in only a third of patients following treatment with first-line antidepressant. There is a need for novel treatments for treatment-resistant depression (TRD).
Paul David, Sigalas +4 more
openaire +2 more sources
Nortriptyline for Treatment-Resistant Depression [PDF]
The Journal of Clinical Psychiatry, 2003 Up to 30% of patients with major depression fail to respond to an antidepressant trial, with most taking a selective serotonin reuptake inhibitor (SSRI) as initial treatment. While the tricyclic antidepressants might be effective for SSRI nonresponders, they have been relegated to third- and fourth-line treatment.
Andrew A, Nierenberg +8 more
openaire +2 more sources
JAMA psychiatry, 2022 This cohort study examines data for episodes of unipolar major depressive disorder that met criteria for treatment-resistant depression to assess its impact on individuals and society and consider potential prognostic factors.
J. Lundberg +10 more
semanticscholar +1 more source
Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
Experimental and Therapeutic Medicine, 2023 Treatment-resistant depression (TRD) is a challenge for psychiatrists, even after more than seven decades since the first antidepressants were used in clinical practice.
O. Vasiliu
semanticscholar +1 more source
Rethinking treatment-resistant depression to quasi-tenacious depression
European Psychiatry, 2023 With almost one-third of patients with major depression not adequately responsive to treatments, the management of treatment-resistant depression (TRD) has continued to be challenging.
Shokouh Arjmand +2 more
doaj +1 more source
Annals of General Psychiatry, 2023 Background Treatment-resistant depression (TRD) is defined by the European Medicines Agency as a lack of clinically meaningful improvement after treatment, with at least two different antidepressants.
Giuseppe Maina +61 more
semanticscholar +1 more source
Treatment-resistant depression and its diagnosis and treatment
Sichuan jingshen weisheng, 2022 The aim of this study is to explore the diagnostic strategies and options for treatment-resistant depression （TRD）. Despite the well-established efficacy of antidepressants， 20%~30% of depressive patients in the clinic fail to respond or respond poorly ...
Hu Shaohua
doaj +1 more source
Frontiers in Pharmacology, 2018 Introduction: It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health.
Leor Roseman, D. Nutt, R. Carhart-Harris
semanticscholar +1 more source
Neuropsychopharmacology, 2021 This study aimed to investigate the role of baseline levels of peripheral inflammation when testing the efficacy of antidepressant augmentation with minocycline in patients with treatment-resistant depression.
M. Nettis +15 more
semanticscholar +1 more source
Molecular Psychiatry, 2021 Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined.
L. Sforzini +60 more
semanticscholar +1 more source